Key result
Selective MMP12 inhibition attenuates myocardial fibrosis and improves cardiac conduction in vivo.
Why the study?
The mechanisms by which granulomatous inflammation in cardiac sarcoidosis is converted into fibrotic remodeling at the macrophage effector function level remain unknown.
Does selective MMP12 inhibition attenuate myocardial fibrosis and improve cardiac conduction in a mouse model of cardiac sarcoidosis?
Does selective MMP12 inhibition attenuate myocardial fibrosis and improve cardiac conduction in a mouse model of cardiac sarcoidosis?
MMP12 drives fibrogenic macrophage differentiation and cardiac fibrosis in sarcoidosis, and its inhibition offers a targeted therapeutic strategy distinct from upstream mTORC1 blockade.
Identifies MMP12 as a potential non-immunosuppressive therapeutic target for cardiac.
No takes yet. Share an insight, caveat, or question.
Mazic et al. (2026) studied Cardiac sarcoidosis. MMP12 inhibition (linvemastat and aderamastat) vs. Vehicle control was evaluated on Myocardial fibrosis and cardiac conduction. Selective MMP12 inhibition disrupted granuloma architecture, reduced fibroblast activation, and attenuated myocardial fibrosis in vivo, yielding a concomitant improvement in cardiac conduction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: